1.北京中医药大学研究生院，北京，100029
2.中国中医科学院西苑医院，北京，100091
扫 描 看 全 文
徐钰莹, 杨宇飞. 杨宇飞教授阶段辨治晚期结直肠癌的中西医并重思路与经验总结[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.09.005
XU Yuying, YANG Yufei. Professor YANG Yufei's Thoughts and Experience Summary on the Treatment of Advanced Colorectal Cancer by Paying Equal Attention to Traditional Chinese and Western Medicine[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.09.005
徐钰莹, 杨宇飞. 杨宇飞教授阶段辨治晚期结直肠癌的中西医并重思路与经验总结[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.09.005 DOI：
XU Yuying, YANG Yufei. Professor YANG Yufei's Thoughts and Experience Summary on the Treatment of Advanced Colorectal Cancer by Paying Equal Attention to Traditional Chinese and Western Medicine[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.09.005 DOI：
结直肠癌具有高发病率与高死亡率，晚期结直肠癌大多无法治愈，虽然西医常规治疗为患者带来生存获益，但疾病本身引起的症状与西医治疗带来的不良反应往往使患者痛苦不堪，严重影响患者的生命质量。除此之外，晚期结直肠癌的西医常规治疗无法覆盖所有人群，对于部分经济基础差、体弱、高龄、西医治疗意愿不强而拒绝或无法接受西医常规治疗的患者来说，迫切需要新的治疗方式弥补常规治疗的缺口，扩大治疗覆盖面。中医药治疗肿瘤历史悠久，在减轻晚期结直肠癌西医治疗不良反应、增加治疗疗效、延长生存期、提高生命质量方面发挥重要作用。杨宇飞教授认为晚期结直肠癌的治疗不能单靠中医或西医一种治疗手段，强调中西医并重是晚期结直肠癌的核心治疗策略，以人为本是要坚持的治疗理念，要在不同疾病发展阶段根据患者的治疗意愿、疾病特征与个人体质灵活选用中医为主或者西医为主、中医为辅或中西医相辅相成的中西医并重治疗策略。在遣方用药时扶正祛邪是晚期结直肠癌治疗核心，健脾补肾解毒是治疗首推之法，根据病情的不同发展阶段与患者所处的西医不同治疗阶段，灵活调节扶正祛邪比例，最终达到提高晚期结直肠癌患者生命质量，延长生存期的目的。
Colorectal cancer (CRC) has high morbidity and mortality, the most advanced CRC cannot be cured. Although conven-tional Western medicine treatment brings survival benefits to patients, the symptoms caused by the disease itself and the adverse reactions caused by Western medicine treatment often make patients miserable and seriously affect the quality of life. In addition, conventional Western medicine treatment for advanced colorectal cancer cannot cover all the population. For some patients who have poor economic foundation, frail, elderly, and poor willingness to treat by Western medicine and refuse or cannot accept con-ventional Western medicine treatment, there is an urgent need for new treatments. The treatment method makes up for the gap of conventional treatment and expands the coverage of treatment. Traditional Chinese medicine has a long history in the treatment of tumors, and it plays an important role in reducing the side effects of Western medicine treatment of advanced colorectal cancer, in-creasing the therapeutic effect, prolonging the survival period, and improving the quality of life. Prof. YANG believes that the treatment of advanced colorectal cancer cannot rely solely on traditional Chinese medicine or Western medicine. She putequal em-phasis on traditional Chinese and Western medicine as the core treatment strategy for advanced colorectal cancer. People-oriented is the treatment concept to be adhered to. It should be based on patients at different stages of disease development. For his treat-ment willingness, disease characteristics and personal physique, he flexibly chooses Chinese and Western medicine treatment strat-egies with traditional Chinese medicine as the main or western medicine as the mainstay, Chinese medicine as the auxiliary or com-plementary Chinese and Western medicine. Strengthening the vital qi and eliminating pathogenic qiare the core of the treatment of advanced colorectal cancer when using prescriptions. Strengthening the spleen and kidneys and detoxification is the first treatment method. According to the different development stages of the disease and the different treatment stages of the patient's Western medicine, the ratio of strengthening the body and eliminating pathogens can be flexibly adjusted. We ultimately achieve the pur-pose of improving the quality of life of advanced colorectal cancer and prolonging the survival period.
杨宇飞晚期结直肠癌中西医并重中医药健脾补肾解毒扶正祛邪治疗经验
Professor YANG YufeiAdvanced colorectal cancerPay equal attention to traditional Chinese and Western medi-cineTraditional Chinese medicineInvigorating kidney and strengthening spleen and detoxificationStrengthening vital qi to elim-inate pathogenic factorTreatment experience
International Agency for Research on Cancer. Latest global cancer da-ta: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL]. (2020-12-15)https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020.
Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer inci-dence by anatomic site and disease stage in the United States from 1976 to 2005[J]. Am J Clin Oncol, 2011, 34(6): 573-580.
Qiu T, Chen W, Li P, et al. Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with meta-static colorectal cancer[J]. Onco Targets Ther, 2018, 11(1): 465-471.
Tran B, Wong H L, Field K M, et al. Resection of colorectal cancer(CRC)metastases in routine practice[J]. J Clin Oncol, 2014, 32(3): 599-599.
Wang Y, Liu P, Fang Y, et al. The Effect of Long-Term Traditional Chinese Medicine Treatment on Survival Time of Colorectal Cancer Based on propensity Score Matching: A Retrospective Cohort Study[J]. Evid Based Complement Alternat Med, 2020, 2020: 7023420.
Yeh MH, Chiu HP, Wu MC, et al. Integrated Chinese Herbal Medicine and Western Medicine on the Survival in Patients with Colorectal Cancer: A Retrospective Study of Medical Records[J]. Evid Based Complement Alternat Med, 2020, 2020: 4561040.
Shao C, Zuo Q, Lin J, et al. Effect of Chinese Herbal Medicine on the Survival of Colorectal Cancer Patients With Liver-Limited Metastases: A Retrospective Cohort Study, 2008 to 2017[J]. Integr Cancer Ther, 2019, 18: 1534735419883687.
Chien TJ, Liu CY, Lu RH, et al. Therapeutic efficacy of Traditional Chinese medicine, “Kuan-Sin-Yin”, in patients undergoing chemo-therapy for advanced colon cancer-A controlled trial[J]. Complement Ther Med, 2016, 29(10): 204-212.
贾小强, 徐仁忠, 郑杰, 等. 北京市基本医保结直肠癌3046例住院费用影响因素分析[J]. 世界科学技术—中医药现代化, 2011, 13(6): 948-951.
杨宇飞, 陈崭新, 许云, 等. 祛邪胶囊对晚期结直肠癌患者生存期和生活质量的随机对照研究[J]. 中国中西医结合杂志, 2008, 28(2): 111-114.
张彤. 祛邪胶囊治疗晚期大肠癌疗效和中医治疗大肠癌获益人群特征分析[D]. 北京: 中国中医科学院, 2018.
Zhang T, He WT, Zi MJ, et al. Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine[J]. Chin J Integr Med, 2018, 24(8): 573-578.
徐钰莹, 孙凌云, 张长, 等. 晚期结直肠癌中医受益人群特征分析[J]. 中国中西医结合杂志, 2019, 39(7): 804-809.
徐钰莹, 张文丽, 杨宇飞, 等. 晚期结直肠癌中医药干预治疗疗效预测模型的建立与应用[J]. 世界科学技术-中医药现代化, 2019, 21(7): 1518-1524.
唐武军, 王笑民. 郁仁存治疗肿瘤“内虚学说”初探[J]. 北京中医药, 2011, 30(3): 186-188.
程海波, 吴勉华. 周仲瑛教授“癌毒”学术思想探析[J]. 中华中医药杂志, 2010, 25(6): 866-869.
何立丽, 孙桂芝. 孙桂芝关于恶性肿瘤病因病机“二本”学说[J]. 中国中医药信息杂志, 2010, 17(1): 88-89.
National Comprehensive Cancer Network. (NCCN)Clinical Practice Guidelines in Oncology. Colon Cancer[EB/OL]. (2021-1-21). https://www.nccn.org/patientshttps://www.nccn.org/patients.
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocar-cinoma, Version 2.2021, NCCN Clinical Practice Guidelines in On-cology[J]. J Natl Compr Canc Netw, 2021, 19(4): 439-457.
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)结直肠癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020: 56-75.
Dienstmann R, Salazar R, Tabernero J. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer[J]. Am Soc Clin Oncol Educ Book, 2018, 3(38): 231-238.
Garde Noguera J, Jantus-Lewintre E, Gil-Raga M, et al. Role of RAS mutation statusasa prognostic factor for patients with advanced colo-rectal cancer treated with first-line chemotherapy based on fluoropyri-midines and oxaliplatin, with or without bevavizumab: A retrospective analysis[J]. Mol Clin Oncol, 2017, 6(3): 403-408.
刘敏, 张洽, 凌丰宇, 等. 阿帕替尼联合替吉奥胶囊治疗晚期胃癌的疗效及安全性的Meta分析[J]. 现代肿瘤医学, 2020, 28(17): 3009-3015.
Boussios S, Pentheroudakis G, Katsanos K, et al. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management[J]. Ann Gastroenterol, 2012, 25(2): 106-118.
Testart-Paillet D, Girard P, You B, et al. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice[J]. Crit Rev Oncol Hematol, 2007, 63(1): 1-11.
田代华. 黄帝内经·素问[M]. 北京: 人民卫生出版社, 2005: 5-88.
杨杨. 俞募配穴埋线治疗慢性放射性肠炎的临床效果[J]. 中外医学研究, 2019, 17(30): 53-55.
顾景艳, 吕亚, 李萍, 等. 保健体疗操联合足三里穴位按摩预防恶性肿瘤患者急性放射性肠炎的效果观察[J]. 护理学报, 2015, 22(13): 57-59.
0
浏览量
6
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公⽹安备110105001699号